A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer

Published:2017-06-01 Issue:1 Volume:7 Page:131-134
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:en
Short-container-title:

Author:

Kurishima Koichi,Watanabe Hiroko,Ishikawa Hiroichi,Satoh Hiroaki,Hizawa Nobuyuki

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM+ cancer stem-like cells via glycolysis;Translational Oncology;2024-11

2. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy;Journal of Thoracic Oncology;2023-07

3. Assessment of Emergency Triage Directives and Wait Times;Journal of Emergency Nursing;2020-11

4. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2020-06-01

5. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study;JNCI: Journal of the National Cancer Institute;2020-04-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP